Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sunshine Biopharma (SBFM) Other Non Operating Income (2016 - 2025)

Sunshine Biopharma's Other Non Operating Income history spans 11 years, with the latest figure at -$2.0 for Q4 2025.

  • For Q4 2025, Other Non Operating Income rose 100.0% year-over-year to -$2.0; the TTM value through Dec 2025 reached $2642.0, up 105.99%, while the annual FY2025 figure was $2642.0, 105.99% up from the prior year.
  • Other Non Operating Income reached -$2.0 in Q4 2025 per SBFM's latest filing, down from $253.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $286535.0 in Q2 2024 to a low of -$340003.0 in Q4 2024.
  • Average Other Non Operating Income over 5 years is -$4737.3, with a median of $15.0 recorded in 2023.
  • The largest YoY upside for Other Non Operating Income was 109883.52% in 2024 against a maximum downside of 871702.56% in 2024.
  • A 5-year view of Other Non Operating Income shows it stood at -$58890.0 in 2021, then skyrocketed by 99.12% to -$521.0 in 2022, then skyrocketed by 92.51% to -$39.0 in 2023, then plummeted by 871702.56% to -$340003.0 in 2024, then soared by 100.0% to -$2.0 in 2025.
  • Per Business Quant, the three most recent readings for SBFM's Other Non Operating Income are -$2.0 (Q4 2025), $253.0 (Q3 2025), and $1940.0 (Q2 2025).